Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years – PROTECT Cohort, July 2021-February 2022

Ashley L. Fowlkes, ScD¹; Sarang K. Yoon, DO²; Karen Lutrick, PhD³; Lisa Gwynn, DO⁴; Joy Burns, PhD⁵; Lauren Grant, MS¹; Andrew L. Phillips, MD²; Katherine Ellingson, PhD⁶; Maria V. Ferraris, MEd, MSPM⁴; Lindsay B. LeClair, MS, MPH⁵; Clare Mathenge⁷; Young M. Yoo, MSPH¹; Matthew S. Thiese, PhD²; Lynn B. Gerald, PhD⁶; Natasha Schaefer Solle, PhD⁴; Zuha Jeddy, MPH⁵; Leah Odame-Bamfo, MPH⁷; Josephine Mak, MPH¹; Kurt T. Hegmann, MD²; Joe K. Gerald, MD⁶; Jezahel S. Ochoa⁴; Mark Berry, PhD⁵; Spencer Rose⁷; Julie Mayo Lamberte, MSPH¹; Purnima Madhivanan, MBBS⁶; Felipe A. Pubillones, DO⁴; Ramona P. Rai, MPH⁵; Kayan Dunnigan, MPH⁷; John T. Jones, MSPH¹; Karl Krupp, PhD⁶; Laura J. Edwards, MPH⁵; Edward J. Bedrick, PhD⁶; Brian E. Sokol, MSPA⁵; Ashley Lowe, PhD⁶; Hilary McLeland-Wieser, MPH⁵; Krystal S. Jovel, MA⁶; Deanna E. Fleary, MSc⁵; Sana M. Khan, MPH⁶; Brandon Poe, MPA⁵; James Hollister⁶; Joanna Lopez, MSPH⁵; Patrick Rivers, MPP³; Shawn Beitel, MSc⁶; Harmony L. Tyner, MD⁸; Allison L. Naleway, PhD⁹; Lauren E.W. Olsho, PhD⁵; Alberto J. Caban-Martinez, DO, PhD⁴; Jefferey L. Burgess, MD⁶; Mark G. Thompson, PhD¹; Manjusha Gaglani, MBBS^7,1